Piper Jaffray Upgrades Sarepta Therapeutic (SRPT) to Overweight
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Piper Jaffray upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Overweight with a price target of $64.00 (from $17.00).
Shares of Sarepta Therapeutic closed at $28.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rosenblatt Upgrades NETGEAR (NTGR) to Buy
- Jefferies Upgrades AK Steel (AKS) to Buy
- Jefferies Cuts Price Target on Parexel (PRXL) to $67 Following Weak 1Q
Create E-mail Alert Related CategoriesAnalyst PT Change, Upgrades
Related EntitiesPiper Jaffray
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!